Drugs / sabarubicin
sabarubicin
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00003982 | Jun 1997 → ? | testicular germ cell tumor | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 1 | NCT00003028 | Apr 1997 → ? | cancer of unknown primary site | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00027781 | Aug 2001 → Mar 2003 | prostate cancer | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sabarubicin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00003028 ↗ |
| Known as | BMS-195615 | “Phase I Study to Determine the Safety of MEN-10755 (BMS-195615) in Patients With a Solid Tumor on a Short I.V. Infusion Given Once Every Week for 3 Consecutive Weeks, Followed...” NCT00003982 ↗ |
| Known as | MEN-10755 | “Sabarubicin (MEN-10755), a new synthetic anthracycline analogue, was evaluated for safety and efficacy in a multicentre phase II study in patients with advanced hormone...” PMID 16337787 ↗ Dec 20051“Phase I Study to Determine the Safety of MEN-10755 (BMS-195615) in Patients With a Solid Tumor on a Short I.V. Infusion Given Once Every Week for 3 Consecutive Weeks, Followed...” NCT00003982 ↗ |
| Known as | Sabarubicina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1230227 ↗ |
| Known as | Sabarubicine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1230227 ↗ |
| Modality | Small molecule | “a new synthetic anthracycline analogue” PMID 16337787 ↗ Dec 2005 |
| Route | Intravenous | “single 15 minute intravenous infusion every 3 weeks” NCT00003028 ↗ |